Wednesday, May 14, 2025
8:00 am Check-In & Light Breakfast
8:50 am Chair’s Opening Remarks
Decoding IBD Heterogeneity with Better Diagnosis for Enhanced Patient Subtyping to Improve Patient Safety & Response Rate in Clinical Trials
9:00 am Leveraging Multi-Omics to Uncover Deeper Insights into IBD Heterogeneity for Improved Patient Subtyping
Synopsis
- How to integrate transcriptomics across diverse cohorts for granular patient subtyping
- Identifying novel markers linked to inflammation signatures to enhance clinical trial outcomes
- How to bridge gaps between phenotypic data and actionable therapeutic strategies in IBD
9:30 am Unlocking the Potential of Tulisokibart & Harnessing Biomarkers to Elevate Response Rate for Therapeutics in IBD
Synopsis
- Sharing insights from the integration of a diagnostic tool in a phase II trial, highlighting successes, challenges, and learnings from its development
- Discussing the role of patient stratification in advancing therapeutic precision and optimizing treatment pathways for IBD
- Exploring the future potential of diagnostic innovations in clinical trials and their role in shaping precision medicine strategies
10:00 am Morning Speed Networking Break
Synopsis
As the Precision Medicine and IBD community come together, this valuable session offers the perfect opportunity to connect with peers and build meaningful relationships. Attendees will have the chance to meet, network, and collaborate with industry leaders driving innovation in IBD care.
Harnessing Prognostic Biomarkers & Monitoring Tools to Enable Personalized Treatment Plans & Revolutionize Therapeutic Efficacy
11:00 am Individual Response Trajectories in IBD Defines Patent Clusters for Precision Medicine
Synopsis
- Large level of individual heterogeneity in patients with IBD including therapy responses
- Response dynamics cluster patients into new subpopulations
- Difference in clinical therapy response are underlaid by biomarker profiles
11:30 am Advancing IBD Precision Therapy Through Multimodal Real-World Data & Agentic AI
Synopsis
• Leveraging expansive patient volumes and deep longitudinal data to identify actionable patterns in IBD
• Harnessing Multimodal AI to integrate clinical, imaging, and molecular data for actionable IBD insights
• Highlighting real-world case studies that illustrate the clinical and research impact of AI-powered analyses
12:00 pm Roundtable Discussion: Advancing Disease Prediction through the Development & Validation of Prognostic Biomarkers for Personalized IBD Treatments
Synopsis
- What is the clinical utility of biomarkers in predicting disease course?
- Can biopharma identify immune profiles linked to patient outcomes in early IBD stages?
- How can we accelerate the validation of biomarkers to enhance treatment efficacy?
12:30 pm Lunch Break & Networking
Bridging Innovation & Implementation: Driving Precision Medicine Forward in IBD Through Data, Technology & Translational Science
1:30 pm Precision Medicine Meets the Real World: Lessons from IBD Plexus
Synopsis
- SPARC IBD is a real world study that follows the natural history of disease for over 6000 IBD patients
- In this presentation, we show the touch points that patients have with the health care system as well as other landmarks in their disease journey
- These interactions are opportunities to learn more about patients or apply treatment strategies in the pursuit of precision medicineÂ
2:00 pm Digital Pathology & Endoscopy in IBD Central Reads: Streamlining Clinical Trials
Synopsis
- Centralized Reads: Centralized review of medical images and videos by expert readers in IBD clinical trials
- Quality Control and Consistency: High-quality results by applying standardized protocols and advanced image analysis tools
- Optimized Workflow: Integrating a customizable workflow to optimize clinical trial design and maximise outcomes
2:10 pm A Novel, Pleiotropic Oral Drug Class that Blocks Gut Migration of Activated T Cells
Synopsis
• Antagonists to retinoic acid receptor-alpha (RARα) block the upregulation of α4β7 and CCR9 during T cell activation in mesenteric lymph nodes
• Daily oral dosing of an RARα antagonist inhibits intestinal epithelial damage in a mouse model of colitis. In separate models, inflammatory T-cell migration to the intestinal lining is also suppressed
• Preclinical safety findings for the highly selective RARα antagonist OR-812 support further development
2:40 pm Poster Session & Afternoon Networking Break
Synopsis
Join the Precision Medicine and IBD community in this interactive session, showcasing pioneering research and innovative approaches in IBD care. Attendees will have the chance to share their work, engage with their peers, and discuss advancements shaping the future of precision medicine for IBD.
Transforming IBD Treatment with Optimized Combination Therapies & Emerging Precision Modalities to Offer More Efficacious Therapeutics
3:30 pm Panel Discussion: Future Horizons in Precision Medicine: Exploring New Modalities & Technologies for IBD
Synopsis
- Discussing emerging therapeutic modalities and their potential to reshape IBD treatment strategies
- Identifying critical challenges and opportunities in developing precision medicine approaches
- Envisioning the integration of novel technologies to improve patient outcomes and drive innovation
- How will combination therapies shape the future of treatments for IBD?
4:30 pm Advancing Combination Therapies to Change the Treatment Paradigm in IBD
Synopsis
- Scientific and clinical rationale for targeting ɑ4β7, TL1A, and IL-23 pathways in IBD therapy
- Nonclinical data demonstrating enhanced efficacy and extended half-life of biologics for combination treatments
- Addressing the natural questions around patient selection for combination therapies: early hypotheses and future directions